65 results about "Hepatic lipid" patented technology

The invention discloses an FAM20B protein and application of an FAM20B protein inhibitor in prevention or treatment of glucolipid metabolism related diseases. Specifically, the invention discloses an application of an FAM20B protein and / or an FAM20B gene in regulation and control of liver glycolipid metabolism. The invention also discloses application of the FAM20B inhibitor in improving, preventing or treating liver glycolipid metabolism disorder or glycolipid metabolism related diseases (such as diabetes, metabolism related fatty liver disease MAFLD, obesity and the like). Experiments show that the FAM20B inhibitor can reduce the liver gluconeogenesis level, relieve impairment of glucose tolerance, relieve hyperglycemia of diabetic patients, reduce the fat content of the whole body and the liver, relieve liver lipid deposition, promote energy consumption, reduce food intake, promote fat burning and reduce liver fat accumulation; the compound can be used for preparing medicines for preventing and treating glucose and lipid metabolism disorder or glucose and lipid metabolism related diseases, and has a wide application prospect in the fields of prevention and treatment of metabolism related diseases.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a duochin in preparation of a medicine for treating MASLD. The research finds that the eriochin has a positive effect on treatment of MASLD, and can effectively delay the body weight, liver weight and liver weight-body weight ratio of MASLD mice, relieve liver injury, relieve liver lipid deposition, liver fatty degeneration, inflammation and fibrosis and delay the MASLD disease progress. Research finds that the eriochin can effectively reduce body weight, relieve liver injury and relieve fatty degeneration and inflammation of the liver, so that MASLD is improved. The invention provides a new thought for the treatment research of MASLD.

This invention discloses a gRNA combination and its application in the preparation of drugs for the prevention of metabolic-associated fatty liver disease (MASLD). The gRNA combination, when mixed with Cas9 protein, yields an RNP complex, which, when microinjected into mouse zygotes, can breed a stable and heritable mouse strain with TMEM68 gene knockout. Combining lipidomics, transcriptomics, and primary hepatocyte functional verification, the core regulatory role of TMEM68 in hepatic lipid metabolism is revealed for the first time systematically. Experiments demonstrate that TMEM68 deficiency significantly reduces the storage of triglycerides (TAG) in the liver and hepatocytes, decreases lipid droplet formation, and reshapes the metabolic homeostasis of various lipids such as glycerophospholipids, cholesterol esters, and bile acids. Therefore, the gRNA combination of this invention, or the RNP complex obtained by mixing the gRNA combination with Cas9 protein, can be used to prepare drugs for the prevention of MASLD, providing a novel intervention strategy for MASLD prevention with broad application prospects.

This invention discloses the application of American ginseng glycoprotein extract in the preparation of drugs for treating alcoholic liver disease, belonging to the field of biomedical technology. This invention verifies that TD can significantly reduce serum ALT, AST, and TG levels in ALD mice, effectively reducing liver damage and lipid accumulation; inhibit NLRP3 protein expression and its downstream targets, effectively alleviating liver inflammation and pyroptosis; and improve intestinal flora imbalance in ALD mice. American ginseng glycoprotein extract has multi-target protective effects against alcoholic liver disease, reducing alcohol-induced liver tissue inflammation and oxidative stress damage. It has a mild composition and high safety profile, and can synergistically exert effects in liver protection, anti-inflammation, and antioxidation, making it suitable for adjunctive intervention and long-term management of alcoholic liver disease, providing a natural, mild, and effective protective pathway for alcoholic liver damage.

The invention discloses application of auricularia auricula monomer polysaccharide ME-2 in preparation of drugs for preventing and treating fatty liver diseases related to metabolic dysfunction. The research of the invention systematically proves that ME-2 has a remarkable intervention effect on the whole course of MASLD for the first time. The invention discloses a breakthrough function of ME-2 as a liver metabolism regulator for the first time: by directly correcting liver lipid metabolism disorder (such as regulating core genes such as Srebp-1c, ACC1, FASN and the like), liver fatty degeneration can be relieved in a dose-dependent manner in the whole course of MASLD, and the serum transaminase level and dyslipidemia can be reduced. Importantly, the curative effect of the traditional Chinese medicine is derived from intervention on a metabolic root source, and is totally different from a known anti-inflammatory application mechanism. Meanwhile, ME-2 has the remarkable advantages of being clear in structure, taking metabolic regulation as a core, and being safe and non-toxic, and a brand new drug candidate is provided for prevention and treatment of MASLD.

The present application relates to a new use of Fuling Gancao Decoction, and specifically discloses application of Fuling Gancao Decoction in treatment of hyperlipidemia, wherein the Fuling Gancao Decoction is composed of the following components in parts by weight: Fuling 2 parts, Guizhi 2 parts, Zhigancao 1 part and Shengjiang 3 parts. It is found through animal experiment research that the Fuling Gancao Decoction can improve the symptoms of hyperlipidemia rats, reduce the content of TG, TC and LDL-C in serum, improve the liver lipid, blood sugar of hyperlipidemia model animals, reduce the liver coefficient, improve the liver cell fatty degeneration, reverse the pathological morphology of adipose tissue cells and the mitochondrial damage of hyperlipidemia model animals. A new indication of the Fuling Gancao Decoction is found, the development of traditional Chinese medicines is promoted, and a new drug composition with less side effects is provided for treatment of hyperlipidemia.

The invention belongs to the technical field of functional microorganism application, and particularly relates to a novel lipid-lowering peptide derived from a probiotic thallus and application thereof, the novel lipid-lowering peptide is a crushed substance derived from a probiotic lactobacillus plantarum thallus, and the molecular weight of the novel lipid-lowering peptide is less than 3kDa. And two key polypeptides APGFGDR (AP7) and TESGAFGR (TE8) are identified from the components, and can specifically inhibit the activities of pancreatic lipase and pancreatic cholesterol esterase. The extracted thallus peptide can be efficiently combined with cholate to inhibit the formation of cholesterol micelles, and has a remarkable inhibiting effect on pancreatic lipase and pancreatic cholesterol esterase. Animal experiments show that the mycopeptide can effectively improve lipid metabolism disorder induced by high fat diet, inhibit weight gain, reduce serum and liver lipid levels and relieve fatty degeneration and inflammation of the liver. The lipid-lowering peptide disclosed by the invention is high in safety and multi-target in action, and can be used for preparing functional products for preventing or treating metabolic diseases such as obesity, hyperlipidemia and the like.

The invention relates to an anti-inflammatory and lipid-lowering-based nano preparation for treating fatty liver and a preparation method of the nano preparation. Galactose modified polyethylene glycol-polylactic acid-glycolic acid copolymer (PEG-PLGA) is used as a targeting carrier, and a lipid-lowering drug fenofibrate and an anti-inflammatory drug curcumin are co-loaded; the particle size of the nano preparation is 150-200nm, and the drug encapsulation efficiency is greater than or equal to 85%. Galactose modified PEG-PLGA is adopted as a carrier, galactose can be specifically combined with an asialoglycoprotein receptor (ASGPR) specifically expressed on the surface of liver cells, active targeting of the liver is achieved, the drug enrichment amount of the liver lesion position is remarkably increased, meanwhile, accumulation of drugs in extrahepatic tissue is reduced, extrahepatic toxicity is effectively reduced, and the drug delivery effect is improved. According to the present invention, the anti-inflammatory drug curcumin and the fenofibrate are combined, such that the biological safety of the preparation is improved, the lipid lowering drug fenofibrate and the anti-inflammatory drug curcumin are innovatively co-loaded, and the fenofibrate and the anti-inflammatory drug curcumin form the synergistic effect system: fenofibrate can activate peroxisome proliferator-activated receptor alpha (PPAR alpha), promote liver lipid catabolism, and reduce lipid deposition;

This invention discloses the use of the SLC7A5 gene or its encoded product as a target in the preparation of drugs for the prevention and / or treatment of metabolic dysfunction-related fatty liver disease (MASLD). This invention reveals for the first time that SLC7A5 is a key node regulating hepatic lipid metabolism, and inhibiting its expression or function can significantly reduce hepatic steatosis, inflammation, and fibrosis. Specifically, this invention relates to pharmaceutical compositions containing SLC7A5 inhibitors, said inhibitors including small molecule compounds, specific antibodies, nucleic acid interfering agents, or gene editing tools. Furthermore, this invention provides a drug screening method for MASLD, which combines molecular docking virtual screening technology with target specificity verification steps, and the application of SLC7A5 as a biomarker in disease diagnosis, staging, and efficacy monitoring. This invention provides definite new targets and candidate drugs with well-defined mechanisms for the clinical diagnosis and treatment of MASLD.

The invention belongs to the technical field of biological medicine, and particularly relates to application of recombinant Glypican 1 protein in treatment of non-alcoholic steatohepatitis. The Glypican 1 protein can treat non-alcoholic steatohepatitis for the first time, experiments prove that the Glypican 1 protein can improve liver lipid deposition, inflammation, fibrosis and other key pathological characteristics, and particularly, after the serum GPC1 level is increased, the Glypican 1 protein can inhibit high-fat and high-cholesterol diet induced mouse body weight increase, optimize the ratio of liver tissue weight to body weight, and improve the non-alcoholic steatohepatitis. The glucose tolerance and the insulin sensitivity are improved, so that the metabolic disorder is integrally improved; besides, the GPC1 accelerant can directly target macrophages, inhibit expression of pro-inflammatory genes (such as Tnf and Nos2) and relieve cascade reaction of liver inflammation, the anti-inflammatory effect is achieved by inhibiting an ERK1 / 2 phosphorylation pathway in mechanism, an innovative, efficient and flexible solution is provided for NASH treatment on the whole, and the defects of current treatment means are overcome.

The invention discloses an application of a jerusalem artichoke tuber alcohol extract in preparation of a medicine for treating type 2 diabetes mellitus, and belongs to the technical field of medicines, the chemical components of the jerusalem artichoke tuber alcohol extract are mainly flavonoid substances, and the jerusalem artichoke tuber alcohol extract can remarkably recover the weight of a mouse with the type 2 diabetes mellitus and improve glucose metabolism indexes such as fasting blood-glucose and oral glucose tolerance; meanwhile, insulin sensitivity is stimulated to secrete insulin, and the functions of pancreatic beta cells are recovered; in addition, the concentration of biochemical indexes such as total cholesterol and triglyceride in the liver is reduced, lipid metabolism of the liver is improved, and a new direction is provided for research and development of natural plant source hypoglycemic products.

The invention discloses a traditional Chinese medicine composition for treating metabolism-related fatty liver diseases and application thereof, and belongs to the technical field of traditional Chinese medicines. The composition is prepared from 30 g of poria cocos, 30 g of rhizoma atractylodis macrocephalae, 30 g of radix salviae miltiorrhizae, 10 g of fructus crataegi, 15 g of pericarpium citri reticulatae, 15 g of lotus leaves, 10 g of rhizoma alismatis, 15 g of red yeast rice, 10 g of herba artemisiae scopariae and 10 g of emblic leafflower fruit according to The freeze-dried powder is prepared by adopting processes of three times of water extraction, low-temperature vacuum concentration and freeze drying, the extraction efficiency is about 37%, and active ingredients are completely reserved. Animal experiments show that the composition can significantly relieve obesity, improve liver fatty degeneration, reduce liver lipid deposition, repair liver injury, regulate dyslipidemia, improve glucose tolerance and insulin resistance, and inhibit liver lipid synthesis and inflammatory response; and no liver and kidney toxicity is caused by continuous high-dose use. The composition provided by the invention has the advantages of multiple targets, systematic regulation of metabolism, exact curative effect and high safety, and provides a novel effective traditional Chinese medicine scheme for prevention and treatment of metabolism-related fatty liver diseases.

The invention relates to the technical field of traditional Chinese medicine preparations, and discloses a salvia miltiorrhiza salvianolic acid and notoginsenoside composition, and the mass ratio of notoginsenoside to salvianolic acid in the composition is 1: 5 or 5: 3 or 3: 5. The invention further discloses application of the composition in preparation of drugs for preventing and treating vasculopathy related to metabolic syndromes of metabolic organs. The composition disclosed by the invention can be used for remarkably relieving liver lipid deposition induced by high-fat diet and reducing abnormal accumulation of white and beige fat; wherein the optimal compatibility ratio is 1: 5, and the mechanism of playing the role is related to down-regulation of the expression of liver lipid transport key protein CD36; the invention provides a new intervention strategy and compatibility basis for preventing and treating vasculopathy related to metabolic syndrome, and provides a precise intervention thought of'combining diseases and syndromes' for the research of early prevention of atherosclerosis.

This invention discloses a probiotic protein V2016 and its application in the preparation of drugs for treating obesity, belonging to the field of biomedical technology. This invention provides a probiotic protein V2016, the amino acid sequence of which is shown in SEQ ID NO.1. Verification has shown that protein V2016 can efficiently and stably bind to the intestinal receptor ICAM-2, thereby significantly upregulating GLP-1 expression, mediating weight loss, reduced fat accumulation, and improved glucose tolerance; simultaneously, it can also reduce hepatic lipid deposition and inflammation, and promote thermogenesis activation in adipose tissue; at the intestinal microecological level, protein V2016 can improve the intestinal microenvironment, promote the enrichment of butyrate-producing bacteria in the intestine, thereby playing a role in regulating metabolism. In summary, the protein V2016 provided by this invention can be applied to the development of novel functional foods or weight-loss drugs.

The invention relates to the technical field of biological medicines, in particular to polypeptide for treating non-alcoholic fatty liver diseases. The invention provides a novel octapeptide P3-1 (SEQ ID NO: 1) derived from macadamia nuts. The novel octapeptide P3-1 (SEQ ID NO: 1) can remarkably improve liver lipid metabolism disorder, restore liver functions, relieve inflammatory response and increase abundance of probiotics in mice with non-alcoholic fatty liver diseases induced by high fat diet. The polypeptide is small in molecular weight, safe in source and easy to absorb, has good medicinal and health-care food development potential, and provides a safe and effective new way for targeted intervention of the non-alcoholic fatty liver disease.

The invention specifically discloses application of RNA binding protein FXR1 as a target spot in preparation of products for preventing and treating metabolism-related fatty liver diseases and improving glucose and lipid metabolism disorders, and relates to the technical field of biological medicines. By constructing a liver specific knockout mouse (HKO) and high-fat and high-sugar diet induction model, the invention reveals that the RNA binding protein FXR1 is a key pathogenic factor for liver fatty degeneration and metabolic disorder for the first time, and discovers that the deletion of the RNA binding protein FXR1 can significantly improve liver lipid deposition, alleviate liver injury and fibrosis, and can be used for treating liver fatty degeneration and metabolic disorder. The invention can improve the abnormal glucose tolerance and insulin resistance of the whole body, and inhibit the RNA binding protein FXR1 as a new strategy for treating liver glycolipid metabolism and metabolism-related fatty liver diseases.

The present invention relates to a composition for regulating hepatic lipid metabolism, comprising Lactiplantibacillus plantarum OPT-A1 strain deposited under accession number KCTC 15555BP, a culture liquid thereof, a cultured product thereof, or a culture lysate thereof. The composition suppresses lipid accumulation and expression of genes related to lipogenesis in hepatocytes, and enhances expression of genes related to lipid oxidation. In addition, the composition inhibits accumulation of triglycerides in hepatocytes and reduces blood triglyceride levels, total cholesterol levels, and liver injury indices. Furthermore, the composition promotes rapid consumption of lipids in hepatocytes and somatic cells through enhancement of muscle mass, and thus can be advantageously used as a raw material for foods, pharmaceuticals, and the like related to alleviation and treatment of various metabolic diseases.

The invention discloses a Lactobacillus paracasei LZLJ09, a microbial agent thereof and an application of the Lactobacillus paracasei LZLJ09, and belongs to the technical field of microorganisms. The invention provides a novel lactobacillus paracasei strain LZLJ09, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.33474. The lactobacillus paracasei LZLJ09 has various functions of remarkably reducing the serum ethanol level, inhibiting liver index increase and liver lipidation caused by alcoholic liver injury, regulating intestinal flora, enhancing the immune function, having broad-spectrum antibacterial performance and the like at the same time, and has wide application prospects in preparation of products for dispelling the effects of alcohol and protecting the liver.

The invention discloses application of a Reg4 gene in treatment of metabolism-related fatty liver, and relates to the technical field of biomedicine. The Reg4 gene is applied to the aspect of treating obesity and metabolism-related fatty liver; according to the application, by increasing expression of the Reg4 gene, liver lipid deposition, liver cell ballooning and inflammatory infiltration related to the metabolism-related fatty liver are inhibited; the application is realized by inhibiting the processes of de novo synthesis of fat in the liver, liver lipid uptake and fatty acid beta oxidation. The step of inhibiting the de novo synthesis of fat in the liver comprises the step of inhibiting the expression of genes of acetyl coenzyme A carboxylase 1, fatty acid synthase and / or stearoyl coenzyme A desaturase 1. The invention definitely proves that the Reg4 gene has an obvious effect of improving obesity and metabolism-related fatty liver, and can relieve hepatic fatty degeneration and inflammation.

The invention relates to a nano drug delivery system for targeted removal of liver aging cells and regulation and control of oxidative stress as well as a preparation method and application of the nano drug delivery system. The nano drug delivery system comprises cerium-doped zinc-based metal organic framework nanoparticles, a drug loaded in a hollow mesoporous structure of the nanoparticles, and a bone marrow mesenchymal stem cell membrane modified on the surfaces of the nanoparticles. According to the invention, a nano drug delivery system for breaking an'aging-inflammation 'cycle is constructed on the basis of an interaction relationship between aging cells and the non-alcoholic fatty liver disease, and the enrichment efficiency and the residence time of the nano drug delivery system at a non-alcoholic steatohepatitis disease part can be improved; the hollow mesoporous metal organic framework nano particles with the effects of efficiently removing active oxygen and being high in drug loading rate are used for loading drugs, the targeting performance on liver senescent cells, the synergistic effect and safety of removing senescent cells and adjusting the inflammatory environment are improved from the two links of drug delivery and release, and liver lipid metabolism and the inflammatory environment are improved.

The application discloses a compound feed for high-salt-alkaline water aquaculture of large-mouth black bass and a preparation method thereof. The raw material composition comprises 42-46 parts of fish meal, 6-8 parts of pork meal, 5-7 parts of casein, 13-17 parts of soybean meal, 10-14 parts of wheat flour, 4.5-8.5 parts of fish oil, 0.5-2 parts of sodium carboxymethyl cellulose, 1-3 parts of Ca(H2PO4)2, 6-8 parts of microcrystalline cellulose, 0.5-2 parts of premix, and 0.1-1 part of choline chloride. When the fat content is 10wt%-12wt%, the compound feed can improve the lipid metabolism of serum and liver of the large-mouth black bass, protect the liver, improve the immune and antioxidant enzyme activity, reduce the tissue damage induced under high-salt-alkaline water aquaculture, improve the intestinal flora disorder of the large-mouth black bass by increasing the number of intestinal probiotics such as phocaebacterium, and further improve the growth performance, immunity and antioxidant stress capacity of the large-mouth black bass under high-salt-alkaline stress.

The invention discloses goose plasma protein source oligopeptide capable of improving liver lipid metabolism disorder and application of the goose plasma protein source oligopeptide, and relates to the technical field of biology. The goose plasma protein source oligopeptide capable of improving liver lipid metabolism disorder is obtained through screening, and the amino acid sequence is GDWIVK. Animal experiments prove that the goose plasma protein source oligopeptide can effectively reduce the levels of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum and liver affected by high fat diet, increase the content of high-density lipoprotein cholesterol, reduce liver lipid deposition and improve pathological injury of the liver. Meanwhile, the structure and diversity of intestinal flora can be adjusted, the abundance of beneficial bacteria and the content of short-chain fatty acid in excrement are increased, the reaction of colitis is relieved, and the synergistic adjustment effect is achieved through an intestinal tract-liver axis.

The invention discloses a novel intestinal probiotic butyric acid monad and application thereof, the novel intestinal probiotic butyric acid monad is preserved in Guangdong Microbiological Culture Collection Center, and the preservation number is GDMCC No.67648. A mouse model proves that the butyric acid monad can promote synthesis of intestinal TMP (Trimethoprim) by remodeling intestinal steady state, and then the TMP is converted into thiamine. Through intestinal liver circulation, thiamine accumulates in the liver and is further converted into TPP. The process promotes the degradation of BCAs, further regulates the lipid metabolism of the liver, and obviously alleviates the progress of metabolic dysfunction related fatty liver diseases induced by high fat diet.

The invention discloses application of a substance for promoting an IDH3A level in preparation of related products for treating hypercholesterolemia. According to the present invention, the IDH3A overexpression adeno-associated virus 8 (IDH3A-AAV8) is constructed for the first time, and the IDH3A-AAV8 can specifically improve the expression level of the IDH3A gene in the liver so as to effectively reduce the plasma total cholesterol level of the hypercholesterolemia model mouse, improve the liver lipid deposition and finally achieve the effective treatment of the hypercholesterolemia; meanwhile, the correlation between the IDH3A and the hypercholesteremia is disclosed for the first time, and it is proved that the hypercholesteremia can be effectively treated by improving IDH3A gene expression or enhancing IDH3A protein activity.

The application provides stem cell exosomes and a preparation method and application thereof, and belongs to the technical field of biological medicines. The preparation method first carries out first-stage stimulation culture on mesenchymal stem cells by using low oxygen and TUDCA, then carries out recovery culture, and then carries out second-stage stimulation culture by using an FFA-BSA compound system and melatonin, and finally collects culture supernatant and separates stem cell exosomes. Experimental results show that the exosomes can significantly improve the ability of the exosomes to improve liver lipid deposition, reduce the content of triglyceride in liver tissue and reduce the levels of serum ALT and AST. Therefore, the exosomes have a good application prospect in the field of non-alcoholic fatty liver and related metabolic liver disease treatment.

The invention provides application of herpetonol in preparation of a medicine for treating or / and preventing fatty liver diseases. According to the invention, through a mouse model established by high fat diet (HFD) and a cell model induced by free fatty acid (FFA), the influence of herpetolol (HPO) on metabolic dysfunction related fatty liver disease (MASLD) is researched. In addition, through a drug affinity reaction target spot stability experiment (DARTS) and a cell thermal displacement experiment (CETSA), a key target spot of the action of the HPO and an action mechanism of the HPO are identified. Research finds that in an MASLD mouse model, the treatment of the hernol (HPO) significantly alleviates the lipid accumulation and inflammatory infiltration of the liver, and reveals that the hernol directly targets an adiponectin receptor 1 (ADIPOR1), up-regulates the expression of the ADIPOR1, activates an adenylate activated protein kinase (AMPK) pathway and further inhibits the nucleation regulation of sterol regulatory element binding protein 1c (SREBP-1c), thereby providing a potential direction for the treatment strategy of the MASLD.

The invention relates to the technical field of medical apparatus and instruments, and discloses a device for adjuvant therapy of non-alcoholic fatty liver disease, which comprises a pedal type exercise mechanism and an internal friction type damping mechanism, the hollow fixing sleeve is installed at the center of the central rotating shaft and can rotate along with the central rotating shaft, the arc-shaped friction plate can rotate along with the hollow fixing sleeve and forms sliding friction with the friction ring body, and the spiral spring generates friction pressure on the arc-shaped friction plate and the friction ring body. The device for adjuvant therapy of the non-alcoholic fatty liver disease has the advantages of being small in overall size and small in occupied space, meanwhile, motion resistance is provided through internal friction of an annular array layout, and a constant and stable damping effect is achieved, so that the liver mitochondrial function of a patient suffering from the non-alcoholic fatty liver disease is improved, lipid metabolism is promoted, and the curative effect of the non-alcoholic fatty liver disease is improved. Therefore, lipid accumulation and inflammation of the liver are relieved, and the function of adjuvant therapy is achieved.

The invention discloses siRNA targeting ASGR1, a delivery system and application of the siRNA. The siRNA is specifically designed and screened aiming at an ASGR1 target spot, so that the expression of the ASGR1 gene can be efficiently silenced. Meanwhile, the invention constructs a corresponding lipid nanoparticle (LNP) for siRNA delivery, and bile acid is innovatively used for partially replacing a cholesterol component in the traditional LNP. Compared with conventional LNP, by means of modification, the delivery efficiency of siRNA is remarkably improved, the nano-particle uptake capacity of hepatocytes is obviously enhanced, and finally liver lipid deposition can be effectively improved.

The invention discloses Witzia ciliaris LZLJ01 and application thereof, and belongs to the field of microbial technology and medicine. The invention provides a new strain LZLJ01 of Witzia ciliaris, and the preservation number of the new strain LZLJ01 is CGMCC (China General Microbiological Culture Collection Center) NO.33473. The Witzia ciliaris LZLJ01 has various functions of remarkably reducing the serum ethanol level, inhibiting liver index increase and liver lipidation caused by alcoholic liver injury, regulating intestinal flora, enhancing the immune function, having broad-spectrum antibacterial performance and the like, and has wide application prospects in preparation of products for dispelling the effects of alcohol and protecting the liver.